Marksans Pharma Ltd

₹ 64.0 3.23%
02 Feb 12:45 p.m.
About

Marksans Pharma is engaged in the Business of Formulation of pharmaceutical products.

Our key focus areas lie in the OTC & prescription drugs that have wide-ranging applications across fields like Oncology, Gastroenterology, Antidiabetic, Antibiotics, Cardiovascular, Pain Management, Gynaecology, among others. [1]

Key Points

Revenue Mix [1]
Around 30% comes from Pain Management, 18% comes from Anti-Diabetic, 15% comes from Cardiovascular System(CVS), 13% comes from Cough & Cold, and the rest comes from Gastrointestinal, Central Nervous System(CNS), etc.

  • Market Cap 2,900 Cr.
  • Current Price 64.0
  • High / Low 69.6 / 38.6
  • Stock P/E 14.7
  • Book Value 31.1
  • Dividend Yield 0.39 %
  • ROCE 23.9 %
  • ROE 18.5 %
  • Face Value 1.00

Pros

  • Company is almost debt free.
  • Company has delivered good profit growth of 83.7% CAGR over last 5 years

Cons

  • Promoter holding has decreased over last quarter: -4.80%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Sep 2019 Dec 2019 Mar 2020 Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022
256 288 335 331 356 358 330 349 361 363 418 434 453
223 240 266 261 273 267 235 272 301 305 354 361 372
Operating Profit 34 47 69 70 83 91 95 77 60 58 64 73 80
OPM % 13% 16% 21% 21% 23% 25% 29% 22% 17% 16% 15% 17% 18%
8 0 0 0 4 -3 6 6 9 12 15 16 14
Interest 3 2 2 2 2 2 3 1 2 1 5 2 3
Depreciation 5 7 10 7 19 9 1 7 7 9 21 11 14
Profit before tax 34 38 58 61 66 78 97 75 60 60 53 76 78
Tax % 23% 23% 26% 20% 23% 24% 18% 16% 23% 20% 44% 21% 23%
Net Profit 26 30 43 49 51 59 80 63 46 48 30 60 60
EPS in Rs 0.63 0.72 1.04 1.21 1.24 1.44 1.94 1.53 1.11 1.18 0.72 1.46 1.51
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 TTM
305 356 438 630 797 893 767 913 1,000 1,134 1,376 1,491 1,667
378 455 369 512 612 757 722 834 868 942 1,037 1,232 1,392
Operating Profit -73 -100 69 118 185 136 45 78 132 192 340 259 275
OPM % -24% -28% 16% 19% 23% 15% 6% 9% 13% 17% 25% 17% 16%
-78 2 4 4 3 9 7 8 5 0 7 42 58
Interest 44 54 15 19 16 10 7 10 10 9 8 8 10
Depreciation 20 24 16 16 16 28 30 27 23 27 36 45 55
Profit before tax -215 -175 44 86 156 107 15 50 104 157 302 248 267
Tax % -3% -1% -12% 15% 28% 23% 24% 28% 23% 23% 21% 25%
Net Profit -222 -176 49 74 112 83 11 36 80 121 239 187 198
EPS in Rs 1.19 1.87 2.67 1.92 0.22 0.80 1.87 2.95 5.76 4.51 4.87
Dividend Payout % 0% -0% 10% 5% 4% 21% 23% 6% 3% 3% 4% 6%
Compounded Sales Growth
10 Years: 15%
5 Years: 14%
3 Years: 14%
TTM: 19%
Compounded Profit Growth
10 Years: 12%
5 Years: 84%
3 Years: 34%
TTM: -20%
Stock Price CAGR
10 Years: 34%
5 Years: 10%
3 Years: 52%
1 Year: 8%
Return on Equity
10 Years: %
5 Years: 20%
3 Years: 23%
Last Year: 19%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Sep 2022
50 50 52 52 53 53 41 41 41 41 41 41 40
Reserves -115 -220 34 90 326 401 392 430 502 595 846 1,068 1,223
135 179 163 160 89 88 110 118 100 30 34 111 100
436 389 165 202 220 192 209 142 160 236 307 416 305
Total Liabilities 492 385 401 490 676 722 752 731 802 902 1,228 1,636 1,668
279 165 156 146 166 270 267 279 270 303 309 428 438
CWIP 0 0 0 0 0 0 0 0 0 0 12 3 1
Investments 0 0 0 0 0 0 0 0 0 0 0 0 0
213 220 245 344 510 452 484 451 533 599 907 1,205 1,229
Total Assets 492 385 401 490 676 722 752 731 802 902 1,228 1,636 1,668

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
-65 -62 39 65 155 31 14 50 27 233 179 99
25 -3 -5 -4 -33 -123 -21 -39 -13 -60 -45 -42
36 57 -40 -29 17 -58 -3 3 -21 -114 -15 80
Net Cash Flow -5 -9 -7 31 138 -150 -10 15 -7 60 118 137

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Debtor Days 118 116 109 98 84 89 118 71 64 78 72 97
Inventory Days 210 126 112 102 107 120 151 152 215 155 248 216
Days Payable 172 100 81 83 88 85 129 54 78 71 103 102
Cash Conversion Cycle 156 141 141 118 103 124 140 169 202 163 217 211
Working Capital Days -270 -218 37 48 55 95 130 117 133 94 110 138
ROCE % -28% -306% 45% 38% 45% 23% 4% 11% 19% 25% 39% 24%

Shareholding Pattern

Numbers in percentages

Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Jan 2023
48.25 48.25 48.25 48.25 48.25 48.25 48.25 48.25 48.25 48.60 49.00 43.80
3.28 4.69 5.05 4.34 3.14 2.64 2.59 3.46 4.04 4.06 4.23 3.94
0.67 0.30 0.30 0.34 0.56 0.53 0.41 0.47 0.94 0.95 0.96 0.88
47.80 46.76 46.40 47.07 48.05 48.58 48.75 47.82 46.77 46.38 45.79 51.37

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Concalls